行业政策与环境 医药生物行业在人口老龄化和政策支持下具备长期发展潜力，但个股表现可能受到行业政策动态及公司 自身研发投入等因素的影响。 资金面情况 数据显示，2026年1月7日，公司主力资金净流入207.40万元，较前一交易日由净流出转为净流入，显示 短期市场情绪可能有所转强。此前1月5日也曾出现主力资金净流入的情况。 公司基本面 2025年前三季度，公司实现营收4.81亿元，归母净利润9190万元，同比有所下降。投资者可关注后续定 期财务报告的发布。 经济观察网新天地（301277）近期在产品研发和资金面方面有动态更新。 产品研发进展 公司抗流感病毒在研产品磷酸奥司他韦原料药及胶囊正按计划推进。此外，其富马酸亚铁原料药已于 2025年12月获批上市，用于预防和治疗缺铁性贫血，丰富了产品管线。 以上内容基于公开资料整理，不构成投资建议。 ...

中证报中证网讯(王珞)12月9日晚，新天地（301277）发布公告，公司于2025年12月8日收到国家药品监 督管理局核准签发的富马酸亚铁原料药《化学原料药上市申请批准通知书》，通知书有效期至2030年12 月7日。 新天地表示，本次公司取得的富马酸亚铁原料药《化学原料药上市申请批准通知书》，表明该原料药已 符合国家药品注册的有关规定要求，将进一步丰富公司的产品结构，提升市场竞争力。 富马酸亚铁是一种用于预防和治疗缺铁性贫血的铁剂，通过补充铁元素改善血红蛋白合成，缓解贫血相 关症状。 ...

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

Core Viewpoint - The company, New World (301277), has received approval from the National Medical Products Administration for the raw material drug Ferrous Fumarate, which is used to prevent and treat iron deficiency anemia [1] Group 1 - The approval includes the issuance of the "Chemical Raw Material Drug Listing Application Approval Notice" for Ferrous Fumarate [1] - Ferrous Fumarate is an iron supplement that improves hemoglobin synthesis and alleviates symptoms related to anemia [1]